Pindolol: A Review of Its Pharmacology, Pharmacokinetics, Clinical Uses, and Adverse Effects

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

Volumn 2, Issue 3, 1982, Pages 134-147

  Golightly, Larry K ^a  

^a British Columbia Drug and Poison Information Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CLONIDINE; DEBRISOQUINE; DIGITALIS; GUANETHIDINE; HYDRALAZINE; INDOMETACIN; METHYLDOPA; METOPROLOL; PINDOLOL; PRAZOSIN; PROPRANOLOL; RESERPINE; THIAZIDE DIURETIC AGENT;

ADVERSE DRUG REACTION; ANGINA PECTORIS; ATRIOVENTRICULAR BLOCK; BRONCHOSPASM; CARDIOVASCULAR SYSTEM; COLD LIMB; CONGESTIVE CARDIOMYOPATHY; DIGESTIVE SYSTEM; DRUG USE; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; HEART; HYPERTENSION; IMPOTENCE; INTOXICATION; MALE GENITAL SYSTEM; NERVOUS SYSTEM; NEUROTOXICITY; PHARMACOKINETICS; PREGNANCY; RESPIRATORY SYSTEM; REVIEW; THERAPY; TREMOR;

EID: 0020319721     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/j.1875-9114.1982.tb04521.x     Document Type: Article

References (261)

1. Clinical pharmacology of the new beta‐adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic properties
2. Clinical pharmacokinetics of β‐adrenoreceptor blocking drugs
3. Hypertension: which beta‐blocker?
4. Beta‐adrenergic blockade in hypertension
5. Beta‐adrenoceptor blocking drugs in hypertension
6. β‐adrenergic receptor blocking drugs in angina pectoris
7. Beta‐adrenergic antagonists in the treatment of patients with heart disease
8. Clinical pharmacology of propranolol
9. Propranolol in the treatment of hypertension
10. The use of propranolol in hypertension: a review
11. Contemporary medical management of stable angina pectoris
12. Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris
13. Clinical pharmacology of the new beta‐adrenergic blocking drugs. Part 9. Nadolol: a new long‐acting beta‐adrenoceptor blocking drug
14. Metoprolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris
15. Drug therapy: metoprolol
16. Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension
17. Pharmacokinetics, mechanisms of action, indications, and adverse effects of timolol maleate, a nonselective beta‐adrenoreceptor blocking agent
18. β‐adrenergic receptors: recognition and regulation
19. The action of sympathomimetic amines and a new beta‐adrenergic blocking agent (4‐(2‐hydroxy‐3‐isopropylamino‐propoxy)‐indole) on the isolated trachea of guinea pigs
20. Isoproterenol antagonism of cardioselective beta adrenergic receptor blocking agents: a comparative study of human and guinea‐pig cardiac and bronchial beta adrenergic receptors
21. Cardiovascular effects of prinodolol (LB‐46), a potent beta‐adrenergic receptor antagonist
22. Comparison of anti‐arrhythmic action and beta‐blocking potency of LB‐46 and (‐) propranolol
23. β‐adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers
24. Investigations with beta‐adrenoceptor blocking drugs in healthy volunteers
25. Preliminary investigations of a new beta‐adrenoceptive receptor blocking drug, LB46, in man
26. A comparison of intravenous pindolol and propranolol in normal man
27. Measurement of partial agonist activity of pindolol
28. Comparative pharmacodynamics and plasma levels of β‐adrenoceptor blocking drugs
29. The effect of pindolol, a beta‐receptor blocking agent, in heart rate and blood‐pressure during submaximal and maximal exercise
30. Haemodynamics of the new beta‐adrenergic antagonist LB 46 in man
31. Influence of sympathomimetic activity of β‐adrenoceptor blockers on the heart rate and blood pressure responses to graded exercise
32. Studies with LB 46, a new beta‐receptor blocking drug
33. The effects on cardiac muscle of β‐receptor antagonists in relation to their activity as local anaesthetics
34. Comparison of the effects on renin release of beta adrenergic antagonists with differing properties
35. β‐blockers and plasma renin activity in hypertension
36. The effect of pindolol on plasma renin activity in patients with essential hypertension
37. The effect of pindolol on plasma renin activity and blood pressure in hypertensive patients
38. Changes in plasma renin activity and blood pressure after acute and chronic administration of β‐adrenergic receptor‐blocking drugs
39. Acute and long‐term studies of the mechanisms of action of beta‐blocking drugs in lowering blood pressure
40. Elevation of serum potassium during beta blockade: absence of relationship to the renin‐aldosterone system
41. Renal function, body fluid volumes, aldosterone, and noradrenaline during treatment of hypertension with pindolol
42. Effect of pindolol on blood pressure, plasma renin activity, and catecholamines in hypertensive patients
43. Brain concentration of propranolol in relation to hypotensive effect in the rabbit with observations on brain propranolol levels in man
44. Comparative antihypertensive effects and tissue distribution of beta adrenergic blocking drugs
45. Centrally induced hypotensive effects of β‐adrenergic blocking drugs
46. The brain as a possible site for the cardiovascular effects of β‐adrenergic blocking agents in cats
47. Proposed mechanisms for propranolol's antihypertensive effect in essential hypertension
48. Increased plasma noradrenaline concentrations in essential hypertension and their decrease after long‐term treatment with a β‐receptor‐blocking agent (prindolol)
49. Experience with pindolol, a beta‐receptor blocker, in the treatment of hypertension
50. Haemodynamic studies with pindolol in hypertension
51. Haemodynamic effects of pindolol in hypertensive patients
52. Haemodynamic effect of long‐term treatment with pindolol in essential hypertension with special reference to the resistance and capacitance vessels of the forearm
53. Hemodynamic effects of beta‐adrenergic blockade with pindolol, oxprenolol, propranolol, and bufetolol hydrochloride in essential hypertension
54. Increase of total body potassium and decrease of exchangeable sodium after long‐term treatment with a β‐receptor‐blocking agent (prindolol) in essential hypertension
55. Comparative β‐adrenoreceptor‐blocking effects and pharmacokinetics of propranolol and pindolol in hypertensive Africans
56. Beta‐adrenoceptor blocking effects and pharmacokinetics of pindolol: a study in hypertensive Africans
57. Single and multiple dose pharmacokinetics of pindolol
58. Pharmacokinetics of pindolol in man
59. Pindolol pharmacokinetics in relation to time course of inhibition of exercise tachycardia
60. Pharmacokinetics of β‐receptor‐blocking agents in relation to their antihypertensive effect
61. Pindolol: a pharmacokinetic comparison with other beta‐adrenoceptor blocking agents
62. Pindolol: a β‐adrenoceptor blocking agent with a negligible first pass effect
63. Plasma pindolol levels and their significance in the assessment of cardiac beta blockade
64. Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function
65. Pharmacokinetics of intravenous and oral pindolol in hypertensive patients with chronic renal failure
66. Pindolol availability in hypertensive patients with normal and impaired renal function
67. Pindolol in hypertension: a double‐blind trial
68. An evaluation of hypotensive agents
69. The effect of pindolol on exercise‐induced cardiac acceleration in relation to plasma levels in man
70. Beta blockade with pindolol: differential cardiac and renal effects despite similar plasma kinetics in normal and uremic man
71. The effect of food and clopamide on the absorption of pindolol in man
72. Activity and duration of action of pindolol and alprenolol compared in healthy volunteers
73. Relationship between the antihypertensive effect and the drug plasma concentration of pindolol
74. Pindolol: a potent beta adrenergic blocking agent in the treatment of hypertension
75. Duration of action of beta blockers
76. An investigation of the comparative liposolubilities of β‐adrenoceptor blocking agents
77. Cerebrospinal fluid concentrations of propranolol, pindolol and atenolol in man: evidence for central actions of β‐adrenoceptor antagonists
78. Effect of β‐adrenoceptor blocking drugs on EEG
79. Pharmacokinetics of unlabelled and 14C‐labelled pindolol in uraemia
80. Vergleichende untersuchen zur elimination von pindolol (Visken) und antipyrin bei patienten mit lebererkrankungen
81. Relationship between renal function and elimination kinetics of pindolol in man
82. Pindolol in the treatment of hypertension: a multicentre trial in hospital and general practice
83. A controlled trial of prindolol (Visken) in hypertension
84. Treatment of essential hypertension with pindolol
85. The hypotensive action of pindolol (Visken) at different dose levels
86. Treatment of hypertension with a new beta‐blocking agent, pindolol (Visken)
87. Effects of pindolol (LB‐46) in the management of mild to moderate hypertension — a comparative double‐blind study (abstract)
88. Double‐blind factorial trial of prindolol and hydrochlorothiazide in hypertension
89. The antihypertensive effect of a new beta‐blocking agent pindolol compared with chlorthalidone
90. Effect of pindolol on arterial pressure in patients with essential hypertension
91. Randomised study of six beta‐blockers and a thiazide diuretic in essential hypertension
92. Beta‐blockers or diuretics in hypertension? A six year follow‐up of blood pressure and metabolic side effects
93. Treatment of mild to moderate hypertension: diuretic or beta‐blockers?
94. Diuretics, β‐blockers or both as treatment for essential hypertension
95. The 1980 report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure
96. Antihypertensive therapy: new pharmacologic approaches
97. Approach to drug therapy for hypertension
98. Antihypertensive drugs: clinical pharmacology and therapeutic use
99. Errors in the treatment of hypertension
100. Pindolol in the treatment of hypertension: a double‐blind randomized trial
101. Treatment of hypertension in the elderly with pindolol and clopamide
102. Two years' study with a combination of pindolol and clopamide ('Viskaldix') in patients with moderate hypertension
103. Verapamil in the treatment of hypertension
104. Antihypertensive effect of pindolol in patients on diuretics
105. An assessment of pindolol in the general practice management of hypertension
106. Viskaldix in the treatment of essential hypertension: a study on hospital out‐patients
107. Treatment of hypertension with a beta‐adrenoceptor blocker: a multicentre trial with pindolol
108. A multi‐centre general practice trial of a pindolol/clopamide combination ('Viskaldix') in essential hypertension
109. Pindolol (Visken, LB 46) a new treatment for hypertension: report of a multicentric open study
110. The use of prindolol (Visken) in the treatment of hypertension
111. General practice experience with pindolol: a multicentre study
112. Pindolol: a comparison with other antihypertensive drugs and a double‐blind placebo trial
113. Combination therapy of essential hypertension with pindolol (Visken) and hydralazine
114. Prazosin combined with thiazide diuretic and beta‐blocker in the treatment of hypertension
115. Comparison of efficacy and safety of pindolol and alpha‐methyldopa in treatment of mild to moderate hypertension: results of a double‐blind evaluative study
116. A comparison of pindolol and methyldopa in the treatment of hypertension: a hospital monitored trial in general practice
117. A comparison of metoprolol and pindolol in the treatment of essential hypertension
118. Comparison of metoprolol and pindolol in the treatment of mild to moderate hypertension: a double‐blind crossover study
119. A double‐blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension
120. Beta adrenoceptor‐blocking drugs once daily in essential hypertension: a comparison of propranolol, pindolol, and atenolol
121. Adrenergic β‐receptor blockade in essential hypertension: a comparison between pindolol (Visken) and propranolol (Inderal)
122. Double‐blind comparison of two beta‐blocking drugs with previous therapy in the treatment of hypertension
123. A comparison of propranolol and prindolol in the treatment of essential hypertension
124. A comparison of beta adrenergic blocking drugs in the treatment of hypertension
125. Pharmacodynamic properties of β‐adrenergic receptor blocking drugs in man
126. Koronare und linksventrikuläre dynamik dreier substanzen mit unterschiedlicher β‐blockierender wirkung: propranolol, pindolol und practolol
127. Veranderungen der haemodynamick unter dem einfluss der B‐sympathlkolyse bei zwei verschiedenen substanzen unterschiedlichen parmakodynamischen prinzips
128. Effects of beta‐adrenergic blockade on the systolic time intervals
129. Haemodynamic effects of β‐receptor blocking agents and digitalis in ischaemic coronary heart disease with angina pectoris
130. Acute hemodynamic effects of five beta‐adrenoceptor blocking agents in man: the significance of selectivity and intrinsic sympathomimetic activity
131. A comparison of the acute haemodynamic effects of propranolol and pindolol at rest and during supine exercise in man
132. Adrenergic beta receptor blockade: hemodynamic importance of intrinsic sympathomimetic activity at rest
133. Clinical pharmacology of the new beta‐adrenergic blocking drugs. Part 6. A comparison of pindolol and propranolol in treatment of patients with angina pectoris. The role of intrinsic sympathomimetic activity
134. Intrinsic sympathomimetic activity (ISA), a useful feature of the β‐blocker, pindolol (abstract)
135. β‐adrenoceptor antagonists: new drugs and new indications
136. Perspectives in adrenergic beta‐receptor blockade
137. Response to once‐a‐day Visken dosage
138. Antihypertensive treatment with pindolol in one or two doses: a comparative trial
139. Once daily β‐adrenoceptor blockade in hypertension: an ambulatory assessment
140. Once‐a‐day pindolol in hypertension
141. Once daily administration of pindolol in the treatment of hypertension
142. Once a day treatment of hypertension
143. Swedish experience with pindolol once daily in the treatment of hypertension
144. The effect on blood pressure of β‐adrenoceptor blocking drugs administered once daily and their duration of action when therapy is ceased
145. The effect on blood pressure of β‐adrenoreceptor drugs given once daily
146. Initial treatment of the young hypertensive: thiazide diuretic or β‐adrenoreceptor‐blocking agent in a single daily dose?
147. Once‐daily regimen for propranolol anti‐hypertensive therapy
148. One and three doses of propranolol a day in hypertension
149. Single daily dosing of propranolol in hypertension
150. Once daily propranolol in the treatment of mild to moderate hypertension: a dose range finding study
151. Influence of once‐daily administration of β‐adrenoceptor antagonists on arterial pressure and its variability
152. Once‐daily metoprolol in primary hypertension
153. Beta‐blockers: once or three times a day?
154. Effect of nadolol in treatment of hypertension
155. Effects of nadolol β‐blockade on blood pressure in hypertension
156. Long‐term treatment of essential hypertension using nadolol and hydrochlorothiazide combined
157. Once‐daily dosing of timolol in hypertension: a controlled study
158. Synergistic effects of a new beta‐adrenergic blocker (pindolol) and isosorbide dinitrate during exercise in patients with coronary insufficiency
159. Separate and combined effects of pindolol and isosorbide dinitrate in standardized exercise tests of patients with angina pectoris
160. The effect of pindolol and isosorbide dinitrate and their combination on exercise tolerance and ECG changes in angina pectoris
161. Treatment of coexistent angina pectoris and hypertension with prindolol
162. The effect of beta blockade and/or physical training in patients with angina pectoris
163. Pindolol and alprenolol in angina pectoris: a comparative clinical study
164. Pindolol (Visken) and alprenolol (Aptin) in angina pectoris: a comparative clinical study with special reference to ergometer working capacity tests
165. Pindolol (Visken) and angina pectoris: a double‐blind multicentre trial
166. Der beta‐blocker pindolol in der therapie der angina pectoris. Bericht über eine multizentriche kontrolliert studie
167. Effect of intravenous and oral pindolol on exercise tolerance and electrocardiographic changes in angina pectoris
168. Treatment of arrhythmias with pindolol
169. LB‐46, a new β‐adrenergic receptor blocking agent in cardiac arrhythmias
170. Clinical pharmacology of the new beta‐adrenergic blocking drugs. Part 5. Pindolol (LB‐46) therapy for supraventricular arrhythmia: a viable alternative to propranolol in patients with bronchospasm
171. Treatment of chronic atrial fibrillation in the elderly, assessed by ambulatory electrocardiographic monitoring
172. Combined treatment of atrial fibrillation with quinidine and beta blockers
173. Effects of intrinsic sympathetic activity of beta‐blockers on SA and AV nodes in man
174. Effect of LB 46, a new beta‐adrenergic antagonist, in hyperthyroidism
175. Comparison of propranolol and LB 46 (prindolol) on hyperthyroid tachycardia
176. Effect of pindolol, a beta receptor antagonist, in hyperthyroidism
177. Comparison between the effects of pindolol and propranolol on essential tremor
178. Levodopa‐propranolol therapy in parkinsonian tremor (letter)
179. Pindolol‐induced tremor
180. Beta‐blockers in essential tremor (editorial)
181. Clinical trial of LB‐46 (d, 1‐4‐(2‐hydroxy‐3‐isopropylaminopropoxy)indol), an adrenergic beta‐receptor blocking agent in migraine prophylaxis
182. Clinical trial of a beta‐receptor blocking agent (LB 46) in migraine prophylaxis
183. A comparative trial of prindolol, clonidine and carbamazepine in the interval therapy of migraine
184. β‐blockers in migraine prophylaxis (editorial)
185. Effect of pindolol in intraocular pressure
186. Ocular and cardiovascular effects of local and systemic pindolol
187. Chronic autonomic failure with postural hypotension
188. Pindolol in orthostatic hypotension: possible therapy?
189. Pindolol acts as beta‐adrenoceptor agonist in orthostatic hypotension: therapeutic implications
190. Pindolol in orthostatic hypotension (letter)
191. Pindolol in orthostatic hypotension (letter)
192. Pindolol in postural hypotension: the case for caution (letter)
193. Béta bloquants et remplissage vasculaire. A propos d'un case gravissime d'oédeme aigu du poumon
194. Kreislaufkollaps bei vorgeschädigten herzen nach 10 mg propranolol Oder 1,25 mg pindolol
195. Nightmares, asthma, and pindolol
196. Effect on asthma of a new beta blocker, LB‐46 (Viskene) (abstract)
197. Beta‐adrenergic blockade with pindolol in mild to moderate asthma
198. Clinical observations on two beta‐blocking agents (pindolol and practolol) in patients with chronic obstructive lung diseases
199. Influence of pindolol (Visken) on respiratory function in 20 asthmatic patients
200. A comparison of four β‐adrenoceptor antagonists in patients with asthma
201. Cardio‐selective beta‐adrenergic therapy in a patient with asthma and hypertrophic obstructive cardiomyopathy
202. Controlled study of the bronchoconstriction effect of pindolol administered intravenously or orally to patients with unstable asthma
203. β‐adrenoceptor antagonists and respiratory function
204. Drugs that inhibit adrenergic nerves and block adrenergic receptors
205. Electrophysiologic effects of pindolol on atrioventricular conduction in canine heart
206. Cardiac electrophysiologic properties of dl‐propranolol, d‐propranolol, 1‐propranolol and dl‐pindolol in anesthetized dogs
207. β‐adrenergic blockade and atrioventricular conduction impairment
208. Effects of cardioselective and non‐cardioselective beta‐blockade on adrenaline‐induced metabolic and cardiovascular responses in man
209. Severe hypoglycaemia due to beta‐blocking drugs in hemodialysis patients (letter)
210. Rôle du maliate de perhexiline et des beta‐bloquers dans l'apparition d'hypoglycémies graves (letter)
211. Hypoglycémie au cours d'un traitement beta‐bloquer (letter)
212. Hypoglycémie au cours d'un traitement beta bloquer
213. Severe hypoglycaemia caused by physical strain and pindolol therapy
214. The effect of 1‐(indol‐4‐yl‐oxy)‐3‐isopropylamino‐propan‐2‐ol(LB‐46, Visken) on carbohydrate and lipid metabolism
215. Untersuchung zur wirkung von pindolol auf kohlehydrat und fettstoffwechsel bei diabetes mellitus
216. Carbohydrate tolerance during beta‐adrenergic blockade in hypertension
217. Effects of cardioselective and non‐selective β‐blockade on the hypoglycaemic response in insulin dependent diabetics
218. Can β‐blockers be used in diabetic patients?
219. Beta‐blocking agents and antidiabetic drugs
220. Propranolol withdrawal in angina pectoris: a prospective study
221. Propranolol rebound — a retrospective study
222. Propranolol‐withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy
223. Coronary artery syndromes after sudden propranolol withdrawal
224. Acute coronary syndromes following abrupt cessation of oral propranolol therapy
225. Comparative changes of withdrawal phenomena after pindolol (PIND), propranolol (PROP), and metoprolol (MET) (abstract)
226. Mechanism of propranolol withdrawal phenomena
227. Metoprolol withdrawal phenomenon: mechanism and prevention
228. Should propranolol be stopped before surgery?
229. Preoperative propranolol therapy and aortocoronary bypass operation
230. Safety and rationale for continuation of propranolol therapy during coronary bypass operation
231. Myocardial revascularization in patients receiving long‐term propranolol therapy
232. Beta‐adrenoceptor blockade and anesthesia: beta‐adrenoceptor antagonism during anesthesia for coronary artery surgery
233. Clinical pharmacology of the new beta‐adrenergic blocking drugs. Part 10. Beta‐adrenoceptor blockade and coronary artery surgery
234. Propranolol in hypertension during pregnancy
235. Propranolol for the treatment of hypertension in pregnancy
236. Propranolol therapy during pregnancy, labor and delivery: evidence for transplacental drug transfer and impaired neonatal drug disposition
237. Effect on the neonate of propranolol administered during pregnancy
238. Propranolol administration during pregnancy: effects on the fetus
239. Propranolol and pregnancy
240. Propranolol therapy throughout pregnancy: a case report
241. The possible adverse effect of propranolol on the fetus in pregnancies complicated by severe hypertension
242. Systemic lupus erythematosus syndrome induced by pindolol
243. Pindolol and pulmonary fibrosis
244. The effects of pindolol and prazosin on hand blood flow in patients with cold extremities and on treatment with β‐blockers
245. How safe are beta‐blocking drugs?
246. Renal function following a single dose of pindolol in hypertensive patients with varying degrees of renal function
247. Effects of pindolol on renal function
248. Modification of antihypertensive effect on β‐adrenoceptor‐blocking agents by inhibition of endogenous prostaglandin synthesis
249. Effects of indomethacin alone and during diuretic, or β‐adrenoreceptor‐blockade therapy on blood pressure and the renin system in essential hypertension
250. Antihypertensive effect of thiazides (letter)
251. Blood pressure and renin during treatment with pindolol
252. Prindolol in hypertension (letter)
253. Paradoxical effects of pindolol (letter)
254. Paradoxical effect of pindolol (letter)
255. Diminishing hypotensive effect of increasing doses of pindolol in DOCA/saline hypertensive rats
256. Positive relationship between the dosage of pindolol and its antihypertensive effect
257. Andrenoceptor blocking drugs: clinical pharmacology and therapeutic use
258. Clinical pharmacology of the new beta‐adrenergic blocking drugs. Part 4. Adverse effects. Choosing a β‐adrenoceptor blocker
259. β‐blockers in hypertension: how to get the best results